Cited by 127Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index, and 1 are not checked yet.

Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

Open access

Roberts, Ryan D., Lizardo, Michael M., Reed, Damon R., Hingorani, Pooja, Glover, Jason, Allen‐Rhoades, Wendy, Fan, Timothy, Khanna, Chand, Sweet‐Cordero, E. Alejandro, Cash, Thomas, Bishop, Michael W., Hegde, Meenakshi, Sertil, Aparna R., Koelsche, Christian, Mirabello, Lisa, Malkin, David, Sorensen, Poul H., Meltzer, Paul S., Janeway, Katherine A., Gorlick, Richard, Crompton, Brian D.·2019·Cancer

DOI 10.1002/cncr.32351PMC PMC6948723

Open this paper in CoChat — free account

Abstract

Patients who are diagnosed with osteosarcoma (OS) today receive the same therapy that patients have received over the last 4 decades. Extensive efforts to identify more effective or less toxic regimens have proved disappointing. As we enter a postgenomic era in which we now recognize OS not as a cancer of mutations but as one defined by p53 loss, chromosomal complexity, copy number alteration, and profound heterogeneity, emerging threads of discovery leave many hopeful that an improving understanding of biology will drive discoveries that improve clinical care. Under the organization of the Bone Tumor Biology Committee of the Children's Oncology Group, a team of clinicians and scientists sought to define the state of the science and to identify questions that, if answered, have the greatest potential to drive fundamental clinical advances. Having discussed these questions in a series of meetings, each led by invited experts, we distilled these conversations into a series of seven Provocative Questions. These include questions about the molecular events that trigger oncogenesis, the genomic and epigenomic drivers of disease, the biology of lung metastasis, research models that best predict clinical outcomes, and processes for translating findings into clinical trials. Here, we briefly present each Provocative Question, review the current scientific evidence, note the immediate opportunities, and speculate on the impact that answered questions might have on the field. We do so with an intent to provide a framework around which investigators can build programs and collaborations to tackle the hardest problems and to establish research priorities for those developing policies and providing funding.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cncr.32351

Cites

93 of 94 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The landscape of genomic alterations across childhood cancers
ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature · doi:10.1038/nature25480 · Cited by 1,572
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · cited 1×
“study, only 1 of the 22 patients with OS had an objective response to single agent pembrolizumab.(81) In the pediatric trial of nivolumab alone or in combination with ip-”
BackgroundSelf-citation
Oxidative stress inhibits distant metastasis by human melanoma cells
Piskounova, E., Agathocleous, M., Murphy, M. M., Hu, Z., Huddlestun, S. E., Zhao, Z., Leitch, A. M., Johnson, T. M., DeBerardinis, R. J., & Morrison, S. J. (2015) · Nature · doi:10.1038/nature15726 · Cited by 1,269
Metastasis: Quantitative Analysis of Distribution and Fate of Tumor Emboli Labeled With 125I-5-Iodo-2′ -deoxyuridine 2 3
Fidler, I. J. (1970) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/45.4.773 · Cited by 1,025
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
Ma, X., Liu, Y., Liu, Y., Alexandrov, L. B., Edmonson, M. N., Gawad, C., Zhou, X., Li, Y., Rusch, M. C., Easton, J., et al. (2018) · Nature · doi:10.1038/nature25795 · Cited by 901
Self-citation
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 900
Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency
Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857
Self-citation
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers
Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752

Flagged first, then by citations

Show all 92 references

Sorted by citations

Osteosarcoma
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Self-citation
Sarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
Self-citation
Future Directions in the Treatment of Osteosarcoma
Smrke, A., Anderson, P. M., Gulia, A., Gennatas, S., Huang, P. H., & Jones, R. L. (2021) · Cells · doi:10.3390/cells10010172 · Cited by 230
A novel photothermally controlled multifunctional scaffold for clinical treatment of osteosarcoma and tissue regeneration
Ma, L., Feng, X., Liang, H., Wang, K., Song, Y., Tan, L., Wang, B., Luo, R., Liao, Z., Li, G., et al. (2020) · Materials Today · doi:10.1016/j.mattod.2019.12.005 · Cited by 211
Improving human cancer therapy through the evaluation of pet dogs
LeBlanc, A. K., & Mazcko, C. N. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0297-3 · Cited by 207
Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies
Hattinger, C. M., Patrizio, M. P., Fantoni, L., Casotti, C., Riganti, C., & Serra, M. (2021) · Cancers · doi:10.3390/cancers13122878 · Cited by 112
Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma
Barani, M., Mukhtar, M., Rahdar, A., Sargazi, S., Pandey, S., & Kang, M. (2021) · Biosensors · doi:10.3390/bios11020055 · Cited by 97
Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
Regan, D. P., Chow, L., Das, S., Haines, L., Palmer, E., Kurihara, J. N., Coy, J. W., Mathias, A., Thamm, D. H., Gustafson, D. L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2105 · Cited by 92
Canine and murine models of osteosarcoma
Beck, J. A., Ren, L., Huang, S., Berger, E. P., Bardales, K., Mannheimer, J., Mazcko, C. N., & LeBlanc, A. K. (2022) · Veterinary Pathology · doi:10.1177/03009858221083038 · Cited by 84
Bone marrow endosteal stem cells dictate active osteogenesis and aggressive tumorigenesis
Matsushita, Y., Liu, J., Chu, A. K. Y., Tsutsumi-Arai, C., Nagata, M., Arai, Y., Ono, W., Yamamoto, K., Saunders, T. L., Welch, J. D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38034-2 · Cited by 75
Bone-targeting exosome nanoparticles activate Keap1 / Nrf2 / GPX4 signaling pathway to induce ferroptosis in osteosarcoma cells
Chen, W., Li, Z., Yu, N., Zhang, L., Li, H., Chen, Y., Gong, F., Lin, W., He, X., Wang, S., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02129-1 · Cited by 71
An update on emerging drugs in osteosarcoma: towards tailored therapies?
Hattinger, C. M., Patrizio, M. P., Magagnoli, F., Luppi, S., & Serra, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1654455 · Cited by 67
TP53 in Biology and Treatment of Osteosarcoma
Synoradzki, K. J., Bartnik, E., Czarnecka, A. M., Fiedorowicz, M., Firlej, W., Brodziak, A., Stasinska, A., Rutkowski, P. L., & Grieb, P. (2021) · Cancers · doi:10.3390/cancers13174284 · Cited by 66
Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas
Menéndez, S. T., Gallego, B., Murillo, D., Rodríguez, A., & Rodrı́guez, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122621 · Cited by 48
Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans
Mannheimer, J., Tawa, G. J., Gerhold, D. L., Braisted, J. C., Sayers, C. M., McEachron, T. A., Meltzer, P. S., Mazcko, C. N., Beck, J. A., & LeBlanc, A. K. (2023) · Communications Biology · doi:10.1038/s42003-023-05208-z · Cited by 52
Self-citation
Localized Nanoparticle‐Mediated Delivery of miR‐29b Normalizes the Dysregulation of Bone Homeostasis Caused by Osteosarcoma whilst Simultaneously Inhibiting Tumor Growth
Freeman, F. E., Dosta, P., Shanley, L. C., Tamez, N. R., Javelly, C. J. R., Mahon, O. R., Kelly, D. J., & Artzi, N. (2023) · Advanced Materials · doi:10.1002/adma.202207877 · Cited by 46
Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach
Schott, C. R., Koehne, A. L., Sayles, L. C., Young, E. P., Luck, C., Yu, K., Lee, A. G., Breese, M. R., Leung, S. G., Xu, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0873 · Cited by 47
Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models
Talbot, L. J., Chabot, A., Ross, A. B., Beckett, A., Nguyen, P., Fleming, A. M., Chockley, P. J., Sheppard, H., Wang, J., Gottschalk, S. M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3298 · Cited by 48
Comparative Immunology and Immunotherapy of Canine Osteosarcoma
Mason, N. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_14 · Cited by 46
Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in human osteosarcoma
Lietz, C. E., Newman, E. T., Kelly, A. D., Xiang, D. H., Zhang, Z., Luscko, C. A., Lozano‐Calderón, S. A., Ebb, D. H., Raskin, K. A., Cote, G. M., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03117-1 · Cited by 45
Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors
Quamine, A. E., Olsen, M. R., Cho, M. M., & Capitini, C. M. (2021) · Cancers · doi:10.3390/cancers13112796 · Cited by 39
Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma
McGuire, J., Nerlakanti, N., Lo, C. H., Tauro, M., Utset‐Ward, T. J., Reed, D. R., & Lynch, C. C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33046 · Cited by 40
Self-citation
A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells
Talbot, L. J., Chabot, A., Funk, A., Nguyen, P., Wagner, J., Ross, A. B., Tillman, H. S., Davidoff, A. M., Gottschalk, S. M., & DeRenzo, C. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691741 · Cited by 39
A Spheroid Model of Early and Late‐Stage Osteosarcoma Mimicking the Divergent Relationship between Tumor Elimination and Bone Regeneration
Freeman, F. E., Burdis, R., Mahon, O. R., Kelly, D. J., & Artzi, N. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101296 · Cited by 36
RETRACTED ARTICLE: Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study
Zhong, S., Hou, Y., Zhang, Z., Guo, Z., Yang, W., Dou, G., Lv, X., Wang, X., Ge, J., Wu, B., et al. (2022) · Bioengineered · doi:10.1080/21655979.2021.2011631 · Cited by 37
Retracted
Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS‐PI3K/AKT Signaling and Attenuated Osteolysis
Liu, L., Geng, H., Mei, C., & Chen, L. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6661534 · Cited by 34
Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma
Yan, P., Wang, J., Yue, B., & Wang, X. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189171 · Cited by 31
LncRNA LOC100129620 promotes osteosarcoma progression through regulating CDK6 expression, tumor angiogenesis, and macrophage polarization
Chen, Y., Tang, G., Qian, H., Chen, J., Cheng, B., Zhou, C., & Shen, Y. (2021) · Aging · doi:10.18632/aging.203042 · Cited by 25
Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center
Evenhuis, R. E., Acem, I., Rueten‐Budde, A. J., Karis, D. S. A., Fiocco, M. F., Dorleijn, D. M. J., Speetjens, F. M., Anninga, J., Gelderblom, H. A. J., & van de Sande, M. A. J. (2021) · Cancers · doi:10.3390/cancers13030486 · Cited by 24
Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma
Robinson, M. J., & Davis, E. J. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01269-2 · Cited by 27
Aberrant Activation of Wound-Healing Programs within the Metastatic Niche Facilitates Lung Colonization by Osteosarcoma Cells
Reinecke, J. B., Garcia, L. J., Gross, A. C., Cam, M., Cannon, M. V., Gust, M. J., Sheridan, J. P., Gryder, B. E., Dries, R., & Roberts, R. D. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0049 · Cited by 25
Self-citation
Loss of RanGAP1 drives chromosome instability and rapid tumorigenesis of osteosarcoma
Gong, Y., Zou, S., Deng, D., Wang, L., Hu, H., Qiu, Z., Wei, T., Yang, P., Zhou, J., Zhang, Y., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2022.12.012 · Cited by 24
Highly Biocompatible Polyester-Based Piezoelectric Elastomer with Antitumor and Antibacterial Activity for Ultrasound-Enhanced Piezoelectric Therapy
Deng, X., Zhao, R., Tang, Y., Yi, M., Ge, Z., Wang, D., Fang, Q., Xiong, Z., Duan, A., Liu, W., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c11749 · Cited by 24
Patterns of metastatic progression and association with clinical outcomes in canine osteosarcoma: A necropsy study of 83 dogs
Silver, K. I., Patkar, S., Mazcko, C. N., Berger, E. P., Beck, J. A., & LeBlanc, A. K. (2023) · Veterinary and Comparative Oncology · doi:10.1111/vco.12927 · Cited by 22
Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p
Liu, Y., Li, G., Feng, J. C., Li, L., Zhang, Y.-T. Y., Zhang, Y., Huang, X., Xu, Y., Zhang, J., Wei, X., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02669-w · Cited by 24
Recent advances in understanding osteosarcoma and emerging therapies
Gaspar, N., Costa, M. E. M. D., Fromigué, O., Droit, R., Berlanga, P., & Marchais, A. (2020) · Faculty Reviews · doi:10.12703/r/9-18 · Cited by 22
Identification of 9-Gene Epithelial–Mesenchymal Transition Related Signature of Osteosarcoma by Integrating Multi Cohorts
Zhang, Y., Ziyun, L., Fu, Q., Xingli, W., & Yang, L. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820980769 · Cited by 21
Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
Xie, L., Xu, J., Sun, X., Li, X., Liu, K., Liang, X., Zhou, Z., Zhuang, H., Sun, K., Wu, Y., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.12813 · Cited by 19
A three-gene signature based on tumour microenvironment predicts overall survival of osteosarcoma in adolescents and young adults
Wen, C., Wang, H., Wang, H., Mo, H., Zhong, W., Tang, J. Y., Lu, Y., Zhou, W., Tan, A., Liu, Y., et al. (2020) · Aging · doi:10.18632/aging.202170 · Cited by 20
Wnt/ß-catenin-mediated p53 suppression is indispensable for osteogenesis of mesenchymal progenitor cells
Zhou, X., Beilter, A., Xu, Z., Gao, R., Xiong, S., Paulucci-Holthauzen, A. A., Lozano, G., Crombrugghe, B. D., & Gorlick, R. G. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03758-w · Cited by 19
Self-citation
Novel circular RNA circATRNL1 accelerates the osteosarcoma aerobic glycolysis through targeting miR-409-3p/LDHA
Zhang, Q., Wang, L., Cao, L., & Wei, T. (2021) · Bioengineered · doi:10.1080/21655979.2021.1985343 · Cited by 19
Translational cell biology of highly malignant osteosarcoma
Roessner, A., Lohmann, C. H., & Jechorek, D. (2021) · Pathology International · doi:10.1111/pin.13080 · Cited by 21
Integrating Radiogenomics and Machine Learning in Musculoskeletal Oncology Care
Kumar, R. R., Sporn, K., Khanna, A., Paladugu, P., Gowda, C., Ngo, A., Jagadeesan, R., Zaman, N., & Tavakkoli, A. (2025) · Diagnostics · doi:10.3390/diagnostics15111377 · Cited by 21
Metastasis‑associated gene MAPK15 promotes the migration and invasion of osteosarcoma cells via the c‑Jun/MMPs pathway
Su, Z., Yang, B., Zeng, Z., Zhu, S., Wang, C., Lei, S., Jiang, Y., & Lin, L. (2020) · Oncology Letters · doi:10.3892/ol.2020.11544 · Cited by 17
Evolving copy number gains promote tumor expansion and bolster mutational diversification
Wang, Z., Xia, Y., Mills, L., Νικολακόπουλος, Α. Ν., Maeser, N., Dehm, S. M., Sheltzer, J. M., & Sun, R. (2024) · Nature Communications · doi:10.1038/s41467-024-46414-5 · Cited by 17
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force
Whittle, S. B., Offer, K., Roberts, R. D., LeBlanc, A. K., London, C. A., Majzner, R. G., Huang, A. Y.-C., Houghton, P. J., Sweet-Cordero, A., Grohar, P. J., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29188 · Cited by 18
Self-citation
Addressing Doxorubicin Resistance in Bone Sarcomas Using Novel Drug-Resistant Models
Gallego, B., Murillo, D., Rey, V., Huergo, C., Estupiñán, Ó., Rodríguez, A., Tornín, J., & Rodrı́guez, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126425 · Cited by 16
Regorafenib for the Treatment of Sarcoma
Blay, J., Duffaud, F., George, S., Maki, R. G., & Penel, N. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00990-0 · Cited by 17
Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma
Walker, R. L., Hornicek, F. J., & Duan, Z. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116342 · Cited by 16
Omic approaches to pediatric bone sarcomas
Tirtei, E., Cereda, M., Luna, E. D., Quarello, P., Asaftei, S. D., & Fagioli, F. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28072 · Cited by 16
Using Liquid Biopsy in the Treatment of Patient with OS
Shulman, D. S., & Crompton, B. D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_9 · Cited by 15
Self-citation
Derepressing nuclear pyruvate dehydrogenase induces therapeutic cancer cell reprogramming
Zhao, T., He, L., Wong, L. P., Mei, S., Xia, J., Xu, Y., Vranken, J. G. V., Mazzola, M. C., Chen, L., Rhee, C., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.05.009 · Cited by 14
Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma
Mills, L. J., Scott, M. C., Shah, P., Cunanan, A. R., Deshpande, A., Auch, B., Curtin, B., Beckman, K. B., Spector, L. G., Sarver, A. L., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115716 · Cited by 14
Precision Medicine in Osteosarcoma: MATCH Trial and Beyond
Tirtei, E., Campello, A., Asaftei, S. D., Mareschi, K., Cereda, M., & Fagioli, F. (2021) · Cells · doi:10.3390/cells10020281 · Cited by 13
Signature based on metabolic‐related gene pairs can predict overall survival of osteosarcoma patients
Li, L., Zhang, L., Yuan, Y., Lu, X., Zhang, Y., Liu, Y., Wen, J., Khader, M. A., Liu, T., Li, J., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3984 · Cited by 14
Metastasis-Initiating Osteosarcoma Subpopulations Establish Paracrine Interactions with Lung and Tumor Cells to Create a Metastatic Niche
Reinecke, J. B., Garcia, L. J., Saraf, A. J., Hinckley, J., Gross, A. C., Pommellet, H. L., Gutpell, K. M., Cam, M., Cannon, M. V., Gust, M. J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3360 · Cited by 13
Self-citation
Impact of limb amputation and cisplatin chemotherapy on metastatic progression in mouse models of osteosarcoma
Ren, L., Huang, S., Beck, J. A., & LeBlanc, A. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-04018-9 · Cited by 13
New drug candidates for osteosarcoma: Drug repurposing based on gene expression signature
Andrade, R. C., Boroni, M., Amazonas, M. K., & Vargas, F. R. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104470 · Cited by 13
Receptor Tyrosine Kinases in Osteosarcoma: 2019 Update
Greenfield, E. M., Collier, C. D., & Getty, P. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_9 · Cited by 13
From biology to personalized medicine: Recent knowledge in osteosarcoma
Mohr, A., Costa, M. E. M. D., Fromigué, O., Audinot, B., Balde, T., Droit, R., Abbou, S. D., Khneisser, P., Berlanga, P., Pérez, E., et al. (2024) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2024.104941 · Cited by 13
Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma
Fu, Y., Yu, J., Liatsou, I., Du, Y., Josefsson, A., Nedrow, J. R., Rindt, H., Bryan, J. N., Kraitchman, D. L., & Sgouros, G. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05888-5 · Cited by 12
Cancer Stem Cells in Sarcomas: In Vitro Isolation and Role as Prognostic Markers: A Systematic Review
Chico, M. Á., Mesas, C., Doello, K., Quiñonero, F., Perazzoli, G., Ortíz, R., Prados, J. C., & Melguizo, C. (2023) · Cancers · doi:10.3390/cancers15092449 · Cited by 12
Low expression of IGFBP4 and TAGLN accelerate the poor overall survival of osteosarcoma
Xi, Y., Liu, J., & Shen, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-13163-8 · Cited by 11
Primary central nervous system sarcomas in adults: A systematic review
Haider, A. S., Palmisciano, P., Sagoo, N. S., Bin-Alamer, O., Ahmadieh, T. Y. E., Pan, E., & Garzón-Muvdi, T. (2022) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2022.107127 · Cited by 10
Tumor and Constitutional Sequencing for Neurofibromatosis Type 1
Tong, S., Devine, W. P., & Shieh, J. T. C. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00540 · Cited by 10
Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma
Torres, H. M., VanCleave, A. M., Vollmer, M. L., Callahan, D., Smithback, A., Conn, J. M., Rodezno, T. G., Gao, Z., Cao, Y. X., Tecleab, Y. A., et al. (2021) · Cancers · doi:10.3390/cancers13164199 · Cited by 10
Modeling phenotypic heterogeneity towards evolutionarily inspired osteosarcoma therapy
Welch, D. L., Fridley, B. L., Cen, L., Teer, J. K., Yoder, S., Pettersson, F. H., Xu, L., Cheng, C., Zhang, Y., Alexandrow, M. G., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-47412-1 · Cited by 8
Self-citation
Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma
Ashton, E., Taly, V., Tlemsani, C., Boudou, P., Percin, S. D., Noel, J., Gaudet-Chardonnet, A., Sullo, F. G., Parfait, B., Abdelli, J., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0134 · Cited by 8
Up-regulation of Core 1 Beta 1, 3-Galactosyltransferase Suppresses Osteosarcoma Growth with Induction of IFN-γ Secretion and Proliferation of CD8+ T Cells
Chen, H., Cai, H., Tang, L., Cegang, F., Zhao, H., Wang, B., & Jia, S. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666221010105701 · Cited by 8
Cold plasma-treated medium preferentially eliminates doxorubicin-resistant osteosarcoma cells
Tornín, J., Gallego, B., Rey, V., Murillo, D., Huergo, C., Rodríguez, A., Canal, C., & Rodrı́guez, R. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.10.394 · Cited by 8
Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma
Collier, C. D., Getty, P. J., & Greenfield, E. M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_4 · Cited by 9
Exploration of the role and mechanism of Rhizoma Paridis total saponins in osteosarcoma based on SPI1/LCN2-mediated ferroptosis
Yang, G., Li, F., Hu, X., Li, M., Liu, Y., Zhu, G., & Tan, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1592862 · Cited by 7
Pathobiology and Molecular Pathways Implicated in Osteosarcoma Lung Metastasis: A Scoping Review
Bashir, A., Ismail, A., Mavadia, A., Ghose, A., Ovsepian, S. V., & Boussios, S. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251359716 · Cited by 10
Bayesian unsupervised clustering identifies clinically relevant osteosarcoma subtypes
Llaneza‐Lago, S., Fraser, W. D., & Green, D. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae665 · Cited by 7
Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway
VanCleave, A. M., Palmer, M., Fang, F., de Oliveira, H. T., Rodezno, T. G., Li, Q., Fuglsby, K., Evans, C. M., Tecleab, Y. A., Ross, A., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27611 · Cited by 7
LRRC15-CAR T Cells for the Treatment of Osteosarcoma
O'Reilly, C., Tuladhar, S., Nguyen, P. T., Sheppard, H., Koo, S. C., Chockley, P. J., Houke, H., Santiago, T., Tian, L., Jeschke, J., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2335 · Cited by 6
Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease
Reed, D. R., Hingorani, P., & Anderson, P. M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_8 · Cited by 6
Self-citation
[Retracted] Increased EHHADH Expression Predicting Poor Survival of Osteosarcoma by Integrating Weighted Gene Coexpression Network Analysis and Experimental Validation
Cui, J., Yi, G., Li, J., Li, Y., & Qian, D. (2021) · BioMed Research International · doi:10.1155/2021/9917060 · Cited by 6
Retracted
Efficacy of tyrosine kinase inhibitors in patients with advanced or metastatic sarcomas after prior chemotherapy: A meta-analysis
Li, W., Liu, L., Liang, Z., Lai, H., Wu, J., Zhang, H., & Fang, C. (2024) · Medicine · doi:10.1097/md.0000000000037423 · Cited by 4
Nanoscale Au@SiO2‑drug/VEGF as an in vivo probe for osteosarcoma diagnosis and therapy
Chen, T., Li, T., & Wang, J. (2021) · Oncology Letters · doi:10.3892/ol.2021.13027 · Cited by 4
Preoperative Predictors of Early Mortality Risk in People with Osteosarcoma of the Extremities Treated with Standard Therapy
Tian, K., Li, P.-J., & Zhang, Y. (2022) · Cancer Management and Research · doi:10.2147/cmar.s340723 · Cited by 4
Exploration of Imaging Biomarkers for Metabolically-Targeted Osteosarcoma Therapy in a Murine Xenograft Model
Huang, S., Ren, L., Beck, J. A., Phelps, T. E., Olkowski, C. P., Ton, A., Roy, J., White, M. E., Adler, S., Wong, K. J., et al. (2023) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2022.0090 · Cited by 4
Increased DEF6 expression is correlated with metastasis and poor prognosis in human osteosarcoma
Zhang, Q., Zhao, G., Cao, Y., Tang, X., Tan, Q., Lü, L., & Guo, Q. (2020) · Oncology Letters · doi:10.3892/ol.2020.11743 · Cited by 4
Genome-Driven Therapy for Chemotherapy-Resistant MetastaticCDK6-Amplified Osteosarcoma
Lazow, M., Johnson, S. L., Johnson, N. D., Breneman, J. C., Dexheimer, P. J., Szabo, S., & Pressey, J. G. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00032 · Cited by 3
YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells
von Ofen, A. J., Thiel, U., Eck, J., Gassmann, H., Thiede, M., Hauer, J., Holm, P. S., & Schober, S. J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1304374 · Cited by 3
ERK phosphorylation is dependent on cell adhesion in a subset of pediatric sarcoma cell lines
Yoon, H., Maron, B. Y., Girald-Berlingeri, S. A., Gasilina, A., Gollin, J., Jian, X., Akpan, I. O., Yohe, M. E., Randazzo, P. A., & Chen, P.-W. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119264 · Cited by 3
Cytokines as Prognostic Biomarkers in Osteosarcoma Patients: A Systematic Review and Meta-analysis
Liu, G., Liu, B., Liu, B., Tang, L., Liu, Z., & Dai, H. (2023) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2023.0083 · Cited by 3
Assisted reproductive technology and association with childhood cancer subtypes
Gulrajani, N. B., Montes, S., McGough, D., Wimberly, C. E., Khattab, A., Semmes, E. C., Towry, L., Cohen, J. L., Hurst, J. H., Landi, D. B., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5114 · Cited by 2
Quantitative expression evaluation of PRAME gene in osteosarcoma
Ishikawa, A. S. K., Tesser‐Gamba, F., Petrilli, A. S., Alves, M. T. D. S., Jesús-García, R., & de Toledo, S. R. C. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08290-y · Cited by 2
In vitro characterization of OSA-424 and OSA-55: new canine models for osteosarcoma research
Zhou, H., Wang, X., Umar, T., Li, W., He, L., Feng, W., Zhang, J., Chen, N., Deng, G., & Qiu, C. (2025) · Veterinary Quarterly · doi:10.1080/01652176.2025.2567523 · Cited by 1
Understanding and Overcoming Osteosarcoma Heterogeneity
Cho, S., Shelmidine, K., & Yustein, J. T. (2026) · Biomolecules · doi:10.3390/biom16060874 · Cited by 1
ANTIPROLIFERATIVE EFFECTS OF VITAMIN K2 IN OSTEOSARCOMA CELLS: COMPARISON OF DIFFERENT CYTOTOXICITY ANALYZES
Özalper, B., Sancı, T. Ö., & Özgüner, M. (2023) · SDÜ Tıp Fakültesi Dergisi · doi:10.17343/sdutfd.1099504 · Cited by 1
Clinical, pathologic and molecular findings in 2 Rottweiler littermates with appendicular osteosarcoma
Silver, K. I., Mannheimer, J., Saba, C., Hendricks, W. P. D., Wang, G., Day, K. R., Warrier, M., Beck, J. A., Mazcko, C. N., & LeBlanc, A. K. (2024) · Veterinary oncology. · doi:10.1186/s44356-024-00004-1 · Cited by 2
Improving Patients’ Quality of Life After Surgical Treatment of Primary Malignant Bone Tumors Using a Training 3D Model
Drobotun, O. V., Protsenko, V. V., & Ternovyy, N. K. (2025) · Experimental Oncology · doi:10.15407/exp-oncology.2024.04.341 · Cited by 1
Repurposing riluzole as an anti-osteosarcoma agent
Jung, O., Rajasekhar, V. K., Azeem, S. M., ChandThakuri, S., Norton, B., Healey, J. H., & Mahajan, S. S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1508819 · Cited by 1
Osteoidbildende Knochentumoren
Roessner, A., Schoeder, V., Smolle, M. A., & Haybäck, J. (2020) · Der Pathologe · doi:10.1007/s00292-020-00763-2 · Cited by 1
Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3pPreprint
Liu, Y., Li, G., Feng, J. C., Li, L., Zhang, Y., Zhang, Y.-T. Y., Huang, X., Xu, Y., Zhang, J., Wei, X., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1521989/v1 · Cited by 1
A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeuticsPreprint
Lietz, C. E., Newman, E. T., Kelly, A. D., Xiang, D. H., Zhang, Z., Ramavenkat, N., Bowers, J. J., Lozano‐Calderón, S. A., Ebb, D. H., Raskin, K. A., et al. (2024) · medRxiv · doi:10.1101/2024.06.19.24309087 · Cited by 1
An incidental finding of osteosarcoma
O’Laughlin, D. J. (2020) · JAAPA · doi:10.1097/01.jaa.0000651760.22729.e9
Localized nanoparticle-mediated delivery of miR-29b normalises the dysregulation of bone homeostasis caused by osteosarcoma whilst simultaneously inhibiting tumour growthPreprint
Freeman, F. E., Dosta, P., Javelly, C. J. R., Mahon, O. R., Kelly, D. J., & Artzi, N. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.09.507272

Authors: Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., Bishop, M. W., Hegde, M., Sertil, A. R., Koelsche, C., Mirabello, L., Malkin, D., Sorensen, P. H., Meltzer, P. S., Janeway, K. A., Gorlick, R., & Crompton, B. D.
Affiliations: Nationwide Children's Hospital (US)
BC Cancer Agency (CA)
Moffitt Cancer Center (US)
Phoenix Children's Hospital (US)
Randall Children's Hospital at Legacy Emanuel (US)
Baylor College of Medicine (US)
University of Illinois Urbana-Champaign (US)
Ethos Vet Health Woburn Massachusetts
Division of Hematology and Oncology, Department of Pediatrics University of California San Francisco San Francisco California
Emory University (US)
St. Jude Children's Research Hospital (US)
University of Arizona (US)
Heidelberg University (DE)
National Institutes of Health (US)
University of Toronto (CA)
Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
The University of Texas MD Anderson Cancer Center (US)
Broad Institute (US)
Corresponding author: Crompton, Brian D.
ORCID: Roberts, Ryan D.
Lizardo, Michael M.
Reed, Damon R.
Hingorani, Pooja
Glover, Jason
Allen‐Rhoades, Wendy
Fan, Timothy
Bishop, Michael W.
Hegde, Meenakshi
Koelsche, Christian
Mirabello, Lisa
Malkin, David
Sorensen, Poul H.
Meltzer, Paul S.
Janeway, Katherine A.
Gorlick, Richard
Crompton, Brian D.
Venue: Cancer
Publisher: Wiley
Published: 2019-07-29
Volume: 125
Issue: 20
Pages: 3514-3525
ISSN: 0008-543X (ISSN-L)
1097-0142
DOI: 10.1002/cncr.32351
PMC: PMC6948723
OpenAlex: W2966831493
Cited by: 127
References: 92
Citations by year: 2026: 7 · 2025: 13 · 2024: 15 · 2023: 18 · 2022: 29 · 2021: 24 · 2020: 19 · 2019: 2
FWCI: 3.12
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (U10CA180886, K08CA188073, K08CA201638)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: osteosarcoma, p53 deficiency, copy number alterations, tumor heterogeneity, carcinogenesis, epigenomics, lung metastasis, preclinical models, translational research, research priorities, Children's Oncology Group
MeSH terms: Child, Humans, Mutation, Osteosarcoma, Tumor Suppressor Protein p53, Genomics, Proteomics, Translational Research, Biomedical, Epigenomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks